WELIREG (belzutifan)
ANTINEOPLASTIC - HYPOXIA INDUCIBLE FACTOR (HIF) INHIBITORS · RENAL CELL CARCINOMA ·+3
Merck Sharp & Dohme
Drug class
Antineoplastic - Hypoxia Inducible Factor (HIF) Inhibitors
Antineoplastic hypoxia-inducible factor (HIF) inhibitors are a class of targeted anticancer therapies designed to block the activity of hypoxia-inducible transcription factors, most notably HIF-2a. Read more about Antineoplastic - Hypoxia Inducible Factor (HIF) Inhibitors
1 drugs in this class 1 manufacturers
Drugs in Antineoplastic - Hypoxia Inducible Factor (HIF) Inhibitors
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Hypoxia Inducible Factor (HIF) Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic hypoxia-inducible factor (HIF) inhibitors are a class of targeted anticancer therapies designed to block the activity of hypoxia-inducible transcription factors, most notably HIF-2a.
Under hypoxic conditions or in tumors with inactivated von Hippel-Lindau tumor suppressor proteins, aberrant HIF accumulation drives downstream transcription of genes critical for angiogenesis, cellular proliferation, and metastasis.
By binding to the factor and disrupting its functional heterodimerization, these agents selectively suppress oncogenic signaling and halt tumor progression.
Clinically, members of this class, such as belzutifan, are utilized in managing advanced clear cell renal cell carcinoma as well as malignancies associated with von Hippel-Lindau disease, including central nervous system hemangioblastomas and pancreatic neuroendocrine tumors.
-
fda.gov
Antineoplastic hypoxia-inducible factor (HIF) inhibitors are a class of targeted anticancer therapies designed to block the activity of hypoxia-inducible transcription factors, most notably HIF-2α Under hypoxic conditions or in tumors with inactivated von Hippel-Lindau tumor suppressor proteins, aberrant HIF accumulation drives downstream transcription of genes critical for angiogenesis, cellular proliferation, and metastasis By binding to the factor and disrupting its functional heterodimerizat...
-
nih.gov
Antineoplastic hypoxia-inducible factor (HIF) inhibitors are a class of targeted anticancer therapies designed to block the activity of hypoxia-inducible transcription factors, most notably HIF-2α
-
youtube.com
Under hypoxic conditions or in tumors with inactivated von Hippel-Lindau tumor suppressor proteins, aberrant HIF accumulation drives downstream transcription of genes critical for angiogenesis, cellular proliferation, and metastasis
-
fda.gov
Clinically, members of this class, such as belzutifan, are utilized in managing advanced clear cell renal cell carcinoma as well as malignancies associated with von Hippel-Lindau disease, including central nervous system hemangioblastomas and pancreatic neuroendocrine tumors
-
fda.gov
Clinically, members of this class, such as belzutifan, are utilized in managing advanced clear cell renal cell carcinoma as well as malignancies associated with von Hippel-Lindau disease, including central nervous system hemangioblastomas and pancreatic neuroendocrine tumors
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.